Company intelligence / Profile preview

CLC bio

Ownership: Private
Employees: ~100
Development stage: Other

Overview

CLC bio was a leading Danish provider of advanced bioinformatics software solutions for DNA, RNA, and protein sequence analysis. Its user-friendly platforms were adopted by thousands of organizations worldwide—including major pharmaceutical companies—for next-generation sequencing data management and analysis. The company grew rapidly from its founding in 2005 until its acquisition by QIAGEN in 2013. After the acquisition, its technology became part of QIAGEN’s broader informatics portfolio.

Industry: Drug Discovery Services

Partnerships

Participated in EU-funded FP7 projects such as STATegra and PATHSEEK with leading European scientists/institutionsCollaborations with top ten global pharma companies as customers/users of their platform

Beyond the preview

Go deeper on CLC bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLC bio.

Explore the full profile